Search

Displaying results 3981 - 3990 of 10000 in total
  1. Drug

    Copper oxodotreotide Cu-64

    go.drugbank.com/drugs/DB15873
    Approved

    [A220348] In a head-to-head trial, the former tracer detected twice as many lesions as the latter.[A220348] … [A220348] Copper Cu 64 dotatate has a longer half-life and can be produced once a day as opposed to several times a day, and lower positron energy lending to improved spatial resolution.

  2. Drug

    Lornoxicam

    go.drugbank.com/drugs/DB06725
    ApprovedInvestigational

    Lornoxicam differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug. … Lornoxicam is approved for use in Japan.

  3. Drug

    Methaqualone

    go.drugbank.com/drugs/DB04833
    ApprovedIllicitWithdrawn

    Methaqualone is a sedative-hypnotic drug that is similar in effect to barbiturates, a general central nervous system depressant. … Its use peaked in the early 1970s as a hypnotic, sedative, and muscle relaxant commonly used for insomnia.

  4. Drug

    Glembatumumab vedotin

    go.drugbank.com/drugs/DB05996
    Investigational

    A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.

  5. Drug

    Mitonafide

    go.drugbank.com/drugs/DB19492
    Experimental

    Mitonafide is a small molecule drug. Mitonafide has a monoisotopic molecular weight of 313.11 Da.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Methyprylon

    go.drugbank.com/drugs/DB01107
    ApprovedIllicitWithdrawn

    Methyprylon was withdrawn from the U.S. market in June 1965 and the Canadian market in September 1990 due to adverse events. … Methyprylon is a sedative of the piperidinedione derivative family that was previously used for the treatment of insomnia.

  7. Drug

    Laromustine

    go.drugbank.com/drugs/DB05817
    Investigational

    VNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia, Lymphoma, Lung Cancer, Small Intestine Cancer, and Myelodysplastic Syndromes, among others.

  8. Drug

    Pilaralisib

    go.drugbank.com/drugs/DB11772
    Investigational

    Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). … Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and Breast Cancer, among others.

  9. Drug

    Propacetamol

    go.drugbank.com/drugs/DB09288
    Investigational

    [A32051] It is a derivative of [acetaminophen], or paracetamol, with the molecular formula glycine, N, N-diethyl-,4-(acetylamino)phenyl ester. … Propacetamol is a parenteral formulation of paracetamol and thus, it is a prodrug that is completely hydrolyzed to paracetamol.

  10. Drug

    Halazepam

    go.drugbank.com/drugs/DB00801
    ApprovedIllicitWithdrawn

    Halazepam is a _benzodiazepine_ derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle relaxing effects. … [A1212] This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer, in 2009.[L6226, L6229]